Download PDF
Fortschr Neurol Psychiatr 2014; 82(6): 311-322
DOI: 10.1055/s-0034-1366379
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Glukokortikoide in der Neurologie: Wirkmechanismen, Anwendungen und Nebenwirkungen

Glucocorticoids in Neurology: Mechanism of Action, Applications and Side Effects
J. Finsterer
1   Krankenanstalt Rudolfstiftung, Wien/Österreich
,
M. Frank
2   Erste Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Wien/Österreich
› Author Affiliations
Further Information

Publication History

Publication Date:
05 June 2014 (online)

    Permissions and Reprints

Zusammenfassung

Glukokortikoide sind ein wesentlicher Bestandteil der Therapie neurologischer Erkrankungen. Auch wenn der Wirkmechanismus noch nicht restlos aufgeklärt ist, ist bei vielen immunologischen und nicht-immunologischen Erkrankungen des Zentralnervensystems oder des peripheren Nervensystems die Gabe von synthetischen Glukokortikoiden das Mittel der ersten Wahl. Bei vielen dieser Erkrankungen ist aber der Evidenzgrad für den Nachweis der Wirksamkeit noch zu gering, als dass eine Evidenz-basierte Empfehlung für eine Steroidtherapie ausgesprochen werden könnte. Wegen der vielen akuten und chronischen Nebenwirkungen ist es wichtig, dass die Wirksamkeit in größeren, randomisierten und kontrollierten Studien nachgewiesen wird. Generell sind Glukokortikoide aber aus der Therapie vieler akuter oder chronischer neurologischer Erkrankungen nicht mehr wegzudenken. Die Indikation für eine Glukokortikoid-Therapie sollte aber wegen der vielfach schwachen Evidenzlage für ihre Wirksamkeit immer sorgfältig abgewogen werden.

Abstract

Glucocorticoids represent a cornerstone in the therapy for many neurological disorders. Even though their mechanism of action is still not completely understood, synthetic glucocorticoids are given as first line drugs in a number of immunological and non-immunological disorders of the central or peripheral nervous system. For most of these disorders, however, the level of evidence that glucocorticoids are truly effective is still not sufficient. This is why treatment with glucocorticoids cannot be recommended on an evidenced-based level for many of these disorders. Due to the huge number of acute or chronic side effects, it is essential that the effects are documented by more randomised placebo-controlled cross-over trials. Generally, glucocorticoids can no longer be omitted in the treatment of neurological disorders, the indication to apply glucocorticoids, however, needs to be thoroughly balanced in the light of their many side effects.

Schlüsselwörter

Steroide - Behandlung - Immunologie - Immunsuppression

Key words

steroids - treatment - immunology - immunosuppression
 

  • Literatur

  • 1 Bruton L, Chabner B, Knollman B. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2010
    Google Scholar
  • 2 Faucy AS, Braunwald E, Kasper DL et al. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw Hill Medical; 2008
    Google Scholar
  • 3 Alangari AA. Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med 2010; 5: 133-135
    CrossrefPubMedGoogle Scholar
  • 4 Rüchardt C. Die Entdeckung und die Struktur von Steroiden: Arbeiten von Heinrich Kilian (1855–1945), Adolf Windaus (1876–1959) und Heinrich Wieland (1877–1957). In: 550 Jahre Albert-Ludwigs-Universität Freiburg. Bd. 4. Freiburg: Alber; 2007: 207-210
    Google Scholar
  • 5 Baker ME, Funder JW, Kattoula SR. Evolution of hormone selectivity in glucocorticoid and mineralocorticoid receptors. J Steroid Biochem Mol Biol 2013; DOI: pii: S0960-0760(13)00138-6. 10.1016/j.jsbmb.2013.07.009.
    PubMedGoogle Scholar
  • 6 Hopes. Huntington’s outreach project for education, at Stanford. Glucocorticoids. http://www.stanford.edu/group/hopes/cgi-bin/wordpress/2010/06/glucocorticoids/ (accessed in October 2013)
    PubMedGoogle Scholar
  • 7 Gomes JA, Stevens RD, Lewin JJ et al. Glucocorticoid therapy in neurologic critical care. Crit Care Med 2005; 33: 1214-1224
    CrossrefPubMedGoogle Scholar
  • 8 Milde AS, Böttiger BW, Morcos M. Nebennierenrinde und Steroide. Der Anaesthesist 2005; 54: 639-654
    CrossrefPubMedGoogle Scholar
  • 9 Newton R. Anti-inflammatory glucocorticoids: Changing concepts. Eur J Pharmacol 2013; DOI: pii: S0014-2999(13)00452-4. 10.1016/j.ejphar.2013.05.035.
    PubMedGoogle Scholar
  • 10 Buttgereit F, Brand MD, Burmester GD. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol 1999; 58: 363-368
    CrossrefPubMedGoogle Scholar
  • 11 Vyas S, Maatouk L. Contribution of Glucocorticoids and Glucocorticoid Receptors to the Regulation of Neurodegenerative Processes. CNS Neurol Disord Drug Targets 2013; (in press)
    PubMedGoogle Scholar
  • 12 Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34: 518-530
    CrossrefPubMedGoogle Scholar
  • 13 Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: New signaling mechanisms in health and disease. J Allergy Clin Immunol 2013; DOI: pii: S0091-6749(13)01388-2. 10.1016/j.jaci.2013.09.007.
    PubMedGoogle Scholar
  • 14 Miranda TB, Voss TC, Hager GL. High-throughput fluorescence-based screen to identify factors involved in nuclear receptor recruitment to response elements. Methods Mol Biol 2013; 1042: 3-12
    PubMedGoogle Scholar
  • 15 Gupte R, Muse GW, Chinenov Y et al. Glucocorticoid receptor represses proinflammatory genes at distinct steps of the transcription cycle. Proc Natl Acad Sci USA 2013; 110: 14616-14621
    CrossrefPubMedGoogle Scholar
  • 16 Möhnle P, Uhl E, Briegel J. Glukokortikoide in der Neurointensivmedizin, welche Indikationen sind gesichert?. Journal für Neurologie, Neurochirurgie und Psychiatrie 2008; 9: 7-12
    PubMedGoogle Scholar
  • 17 Chen D, Nishizawa S, Yokota N et al. High-dose methylprednisolone prevents vasospasm after subarachnoid hemorrhage through inhibition of protein kinase C activation. Neurol Res 2002; 24: 215-222
    CrossrefPubMedGoogle Scholar
  • 18 Deutsche Gesellschaft für Neurologie. Leitlinien der neurologischen Therapie. 2013 http://www.dgn.org/component/content/article/45-leitlinien-der-dgn-2012/
    PubMedGoogle Scholar
  • 19 Grauer O, Offenhäusser M, Schmidt J et al. Glucocorticosteroid therapy in optic neuritis and multiple sclerosis. Evidence from clinical studies and practical recommendations. Nervenarzt 2001; 72: 577-589
    CrossrefPubMedGoogle Scholar
  • 20 Ramo-Tello C, Grau-López L, Tintoré M et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2013; (in press)
    PubMedGoogle Scholar
  • 21 Burton JM, O'Connor PW, Hohol M et al. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2012; 12 CD006921 DOI: 10.1002/14651858.CD006921.pub3.
    PubMedGoogle Scholar
  • 22 Nordborg E, Nordborg C. Giant cell arteritis: strategies in diagnosis and treatment. Curr Opin Rheumatol 2003; 16: 25-30
    PubMedGoogle Scholar
  • 23 Moore PM, Richardson B. Neurology of the vasculitides and connective tissue diseases. J Neurol Neurosurg Psychiat 1998; 65: 10-22
    CrossrefPubMedGoogle Scholar
  • 24 Sinico RA, Radice A, Corace C et al. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis. Ann NY Acad Sci 2005; 1050: 185-192
    CrossrefPubMedGoogle Scholar
  • 25 Ribi C, Cohen P, Pagnoux C. French Vasculitis Study Group. et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58: 586-594
    CrossrefPubMedGoogle Scholar
  • 26 Metzler C, Hellmich B, Gause A et al. Churg Strauss syndrome – successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22 (Suppl. 36) S52-S61
    PubMedGoogle Scholar
  • 27 Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5: 25-35
    CrossrefPubMedGoogle Scholar
  • 28 Farah S, Al-Shubaili A, Montaser A et al. Behçet's syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry 1998; 64: 382-384
    CrossrefPubMedGoogle Scholar
  • 29 Appenzeller S, Lilian T, Costallat L et al. Neurolupus. Arch Neurol 2006; 63: 458-460
    CrossrefPubMedGoogle Scholar
  • 30 Irani SR, Bera K, Waters P et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain 2010; 133: 1655-1667
    CrossrefPubMedGoogle Scholar
  • 31 Dalmau J. Limbic encephalitis and variants related to neuronal cell membrane autoantigens. Rinsho Shinkeigaku 2008; 48: 871-874
    CrossrefPubMedGoogle Scholar
  • 32 Lai M, Hughes EG, Peng X et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434
    CrossrefPubMedGoogle Scholar
  • 33 Olmez I, Moses H, Sriram S et al. Diagnostic and therapeutic aspects of Hashimoto's encephalopathy. J Neurol Sci 2013; 331: 67-71
    CrossrefPubMedGoogle Scholar
  • 34 Bahi-Buisson N, Villanueva V, Bulteau C et al. Long term response to steroid therapy in Rasmussen encephalitis. Seizure 2007; 16: 485-492
    CrossrefPubMedGoogle Scholar
  • 35 Brouwer MC, McIntyre P, Prasad K et al. Corticosteroids for acute bacterial meningitis. . Cochrane Database Syst Rev 2013; 6 CD004405 DOI: 10.1002/14651858.CD004405.pub4.
    PubMedGoogle Scholar
  • 36 Van de Beek D, de Gans J, McIntyre P et al. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 2004; 4: 139-143
    CrossrefPubMedGoogle Scholar
  • 37 Pfausler B, Schmutzhard E. Controversies in neurology, Vienna, 2012: steroids in bacterial meningitis: no. J Neural Transm 2013; 120: 343-346
    CrossrefPubMedGoogle Scholar
  • 38 Thwaites GE. Advances in the diagnosis and treatment of tuberculous meningitis. Curr Opin Neurol 2013; 26: 295-300
    CrossrefPubMedGoogle Scholar
  • 39 Schoeman JF, Donald PR. Tuberculous meningitis. Handb Clin Neurol 2013; 112: 1135-1138
    PubMedGoogle Scholar
  • 40 Krysiak R, Kedzia A, Okopień B. Coexistence of glucocorticoid resistance and pseudohypoparathyroidism. West Indian Med J 2012; 61: 928-931
    CrossrefPubMedGoogle Scholar
  • 41 Yang N, Ray DW, Matthews LC. Current concepts in glucocorticoid resistance. Steroids 2012; 77: 1041-1049
    CrossrefPubMedGoogle Scholar
  • 42 Van den Bergh PY, Rajabally YA. Chronic inflammatory demyelinating polyradiculoneuropathy. Presse Med 2013; 42: e203-e215
    CrossrefPubMedGoogle Scholar
  • 43 Cocito D, Paolasso I, Antonini G. Italian Network for CIDP Register et al. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 2010; 17: 289-294
    CrossrefPubMedGoogle Scholar
  • 44 Eftimov F, Winer JB, Vermeulen M et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2013; 12 CD001797 DOI: 10.1002/14651858.CD001797.pub3.
    PubMedGoogle Scholar
  • 45 van Schaik IN. First-line treatment for CIDP: a new piece of the puzzle. Lancet Neurol 2012; 11: 478-479
    CrossrefPubMedGoogle Scholar
  • 46 Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N Engl J Med 1974; 290: 81-84
    CrossrefPubMedGoogle Scholar
  • 47 Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298
    CrossrefPubMedGoogle Scholar
  • 48 Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 2006; 13: 1006-1010
    CrossrefPubMedGoogle Scholar
  • 49 Arsura E, Brunner NG, Namba T et al. High-dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985; 42: 1149-1153
    CrossrefPubMedGoogle Scholar
  • 50 Sullivan FM, Swan IR, Donnan PT et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med 2007; 357: 1598-1607
    CrossrefPubMedGoogle Scholar
  • 51 Engström M, Berg T, Stjernquist-Desatnik A et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2008; 7: 993-1000
    CrossrefPubMedGoogle Scholar
  • 52 Jeong SH, Kim HJ, Kim JS. Vestibular neuritis. Semin Neurol 2013; 33: 185-194
    Google Scholar
  • 53 Karlberg ML, Magnusson M. Treatment of acute vestibular neuronitis with glucocorticoids. Otol Neurotol 2011; 32: 1140-1143
    CrossrefPubMedGoogle Scholar
  • 54 Fishman JM, Burgess C, Waddell A. Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis). Cochrane Database Syst Rev 2011; (05) CD008607 DOI: 10.1002/14651858.CD008607.pub2.
    PubMedGoogle Scholar
  • 55 Pointillart V, Petitjean ME, Wiart L et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 2000; 38: 71-76
    CrossrefPubMedGoogle Scholar
  • 56 Hulbert RJ. Methylprednisolone for acute spinal cord injury: An inappropriate standard of care. J Neurosurg (Spine) 2000; 93: 1-7
    CrossrefPubMedGoogle Scholar
  • 57 Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol 1998; 25: 1995-2002
    PubMedGoogle Scholar
  • 58 McAdam LC, Mayo AL, Alman BA et al. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy. Acta Myol 2012; 31: 16-20
    PubMedGoogle Scholar
  • 59 Fachinformation zu Cortison Ciba® Onlineversion. (accessed October 2013)
    PubMedGoogle Scholar
  • 60 Nassar K, Janani S, Roux C et al. Long-term systemic glucocorticoid therapy: Patients' representations, prescribers' perceptions, and treatment adherence. Joint Bone Spine 2013; pii: S1297-319X(13)00177-2 DOI: 10.1016/j.jbspin.2013.07.001.
    PubMedGoogle Scholar
  • 61 Habib G, Artul S, Hakim G. Annoying Hiccups following Intra-Articular Corticosteroid Injection of Betamethasone Acetate/Betamethasone Sodium Phosphate at the Knee Joint. Case Rep Rheumatol 2013; 2013: 829620 DOI: 10.1155/2013/829620.
    PubMedGoogle Scholar
  • 62 Dooley JM, Bobbitt SA, Cummings EA. The impact of deflazacort on puberty in Duchenne muscular dystrophy. Pediatr Neurol 2013; DOI: pii:S0887-8994(13)00294-4. 10.1016/j.pediatrneurol.2013.05.004.
    PubMedGoogle Scholar
  • 63 Rutter MM, Collins J, Rose SR et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 2012; 22: 1046-1056
    CrossrefPubMedGoogle Scholar
  • 64 Pavlou E, Gkampeta A, Kouskouras K et al. Idiopathic acute transverse myelitis: Complete recovery after intravenous immunoglobulin. Hippokratia 2012; 16: 283-285
    PubMedGoogle Scholar
  • 65 Hall JJ, Hughes CA, Foisy MM et al. Iatrogenic Cushing syndrome after intra-articular triamcinolone in a patient receiving ritonavir-boosted darunavir. Int J STD AIDS 2013; 24: 748-752
    CrossrefPubMedGoogle Scholar
  • 66 Filippini G, Brusaferri F, Sibley WA et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; (04) CD001331
    PubMedGoogle Scholar
  • 67 Darling KE, Niederhauser J, Bervini D et al. Cerebral vasculitis complicating postoperative meningitis: the role of steroids revisited. Swiss Med Wkly 2012; 142: w13697 DOI: 10.4414/smw.2012.13697.
    PubMedGoogle Scholar
  • 68 Gotkine M, Vaknin-Dembinsky A. Central nervous system vasculitis. Curr Treat Options Neurol 2013; 15: 367-374
    CrossrefPubMedGoogle Scholar
  • 69 Kötter I, Henes JC, Wagner AD et al. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012; 30 (Suppl. 70) S114-S129
    PubMedGoogle Scholar
  • 70 Nuñez-Sotelo CM, Gutiérrez-Gonzalez LA, Rodriguez MA. Rapid, complete and sustained response to corticosteroids and pulse cyclophosphamide therapy in a patient with Behçet and central nervous disease. Maedica (Buchar) 2012; 7: 348-351
    PubMedGoogle Scholar
  • 71 Peño IC, De las Heras RV, Carbonell BP et al. Neurobehçet disease: clinical and demographic characteristics. Eur J Neurol 2012; 19: 1224-1227
    CrossrefPubMedGoogle Scholar
  • 72 Fernandes Moça Trevisani V, Castro AA, Neves Neto JF et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2013; 2 CD002265 DOI: 10.1002/14651858.CD002265.pub3.
    PubMedGoogle Scholar
  • 73 Trevisani VF, Castro AA, Neves Neto JF et al. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2006; (02) CD002265
    PubMedGoogle Scholar
  • 74 Hacohen Y, Joseph S, Kneen R et al. Limbic Encephalitis Associated With Elevated Antithyroid Antibodies. J Child Neurol 2013; (in press)
    PubMedGoogle Scholar
  • 75 McKeon A. Immunotherapeutics for Autoimmune Encephalopathies and Dementias. Curr Treat Options Neurol 2013; (in press)
    PubMedGoogle Scholar
  • 76 Hernán MartínezJ, Torres O, Mangual MM et al. Hashimoto’s encephalopathy: an underdiagnosed clinical entity. Bol Asoc Med P R 2013; 105: 57-61
    PubMedGoogle Scholar
  • 77 Kamei S. Clinical diagnosis and treatment of anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. Nihon Rinsho 2013; 71: 904-912
    PubMedGoogle Scholar
  • 78 Kitada M, Suzuki H, Ichihashi J et al. Dramatic improvement in two cases of anti-NMDA receptor encephalitis after immunomodulating therapy. Rinsho Shinkeigaku 2011; 51: 683-687
    CrossrefPubMedGoogle Scholar
  • 79 Wijntjes J, Wouda EJ, Siegert CE et al. Need for prolonged immunosupressive therapy in CLIPPERS a case report. BMC Neurol 2013; 13: 49 DOI: 10.1186/1471-2377-13-49.
    CrossrefPubMedGoogle Scholar
  • 80 Dudesek A, Rimmele F, Tesar S et al. CLIPPERS: Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory CNS disorders. Clin Exp Immunol 2013; (in press)
    PubMedGoogle Scholar
  • 81 Zaffiri L, Verma R, Struzzieri KE et al. Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. New Microbiol 2013; 36: 89-92
    PubMedGoogle Scholar
  • 82 Antoniol C, Jilek S, Schluep M et al. Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?. Neurology 2012; 79: 2258-2264
    CrossrefPubMedGoogle Scholar
  • 83 Greco A, Fusconi M, Gallo A et al. Vogt-Koyanagi-Harada syndrome. Autoimmun Rev 2013; 12: 1033-1038
    CrossrefPubMedGoogle Scholar
  • 84 Nozaki K, Judson MA. Neurosarcoidosis. Curr Treat Options Neurol 2013; 15: 492-504
    CrossrefPubMedGoogle Scholar
  • 85 Lu RP, Keilson G. Combination regimen of methylprednisolone, IV immunoglobulin, and plasmapheresis early in the treatment of acute disseminated encephalomyelitis. J Clin Apher 2006; 21: 260-265
    CrossrefPubMedGoogle Scholar
  • 86 Tenembaum SN. Acute disseminated encephalomyelitis. Handb Clin Neurol 2013; 112: 1253-1262
    PubMedGoogle Scholar
  • 87 Nomura K. Treatment of neuromyelitis optica. Nihon Rinsho 2013; 71: 829-838
    PubMedGoogle Scholar
  • 88 Sato D, Callegaro D, Lana-Peixoto MA et al. Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 2012; 70: 59-66
    CrossrefPubMedGoogle Scholar
  • 89 Ryken TC, McDermott M, Robinson PD et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96: 103-114
    CrossrefPubMedGoogle Scholar
  • 90 Gessi M, Kuchelmeister K, Kellner U et al. Unusual clinico-pathological features in primary Hodgkin's lymphomas of the central nervous system. Acta Neurochir (Wien) 2013; 155: 19-24
    CrossrefPubMedGoogle Scholar
  • 91 Chimienti E, Spina M, Vaccher E et al. Management of immunocompetent patients with primary central nervous system lymphoma. Clin Lymphoma Myeloma 2009; 9: 353-364
    CrossrefPubMedGoogle Scholar
  • 92 Drappatz J. Medical care of patients with brain tumors. Continuum (Minneap Minn) 2012; 18: 275-294
    PubMedGoogle Scholar
  • 93 Török ME, Nguyen DB, Tran TH et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One 2011; 6 (12) e27821 DOI: 10.1371/journal.pone.0027821.
    CrossrefPubMedGoogle Scholar
  • 94 Oehler E. Eosinophilic meningitis. Rev Med Interne 2013; 34: 497-500
    CrossrefPubMedGoogle Scholar
  • 95 Thanaviratananich S, Thanaviratananich S, Ngamjarus C. Corticosteroids for parasitic eosinophilic meningitis. Cochrane Database Syst Rev 2012; (in press)
    PubMedGoogle Scholar
  • 96 Gauri LA, Ranwa BL, Nagar K et al. Post chikungunya brain stem encephalitis. J Assoc Physicians India 2012; 60: 68-70
    PubMedGoogle Scholar
  • 97 Janigro D, Iffland IiPH, Marchi N et al. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia 2013; 54 (Suppl. 06) 30-32
    PubMedGoogle Scholar
  • 98 Abend NS, Dlugos DJ. Treatment of refractory status epilepticus: literature review and a proposed protocol. Pediatr Neurol 2008; 38: 377-390
    CrossrefPubMedGoogle Scholar
  • 99 Tfelt-Hansen PC, Jensen RH. Management of cluster headache. CNS Drugs 2012; 26: 571-580
    CrossrefPubMedGoogle Scholar
  • 100 Chen PK, Chen HM, Chen WH. Treatment Guideline Subcommittee of the Taiwan Headache Society et al. Treatment guidelines for acute and preventive treatment of cluster headache. Acta Neurol Taiwan 2011; 20: 213-227
    PubMedGoogle Scholar
  • 101 Strenger V, Lackner H, Mayer R et al. Incidence and clinical course of radionecrosis in children with brain tumors A 20-year longitudinal observational study. Strahlenther Onkol 2013; 189: 759-764
    CrossrefPubMedGoogle Scholar
  • 102 Nasr Ben Ammar C, Chaari N, Kochbati L et al. Brain radionecrosis in patients irradiated for nasopharyngeal carcinoma: about nine cases. Cancer Radiother 2007; 11: 234-240
    CrossrefPubMedGoogle Scholar
  • 103 Menotta M, Biagiotti S, Bianchi M et al. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity. J Biol Chem 2012; 287: 41352-41363
    CrossrefPubMedGoogle Scholar
  • 104 Zannolli R, Buoni S, Betti G et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 2012; 27: 1312-1316
    CrossrefPubMedGoogle Scholar
  • 105 Namekawa M, Nakamura Y, Nakano I. Cortical involvement in Marchiafava-Bignami disease can be a predictor of a poor prognosis: a case report and review of the literature. Intern Med 2013; 52: 811-813
    CrossrefPubMedGoogle Scholar
  • 106 Tao H, Kitagawa N, Kako Y et al. A case of anorexia nervosa with Marchiafava-Bignami Disease that responded to high-dose intravenous corticosteroid administration. Psychiatry Res 2007; 156: 181-184
    CrossrefPubMedGoogle Scholar
  • 107 Hillbom M, Saloheimo P, Fujioka S et al. Diagnosis and management of Marchiafava-Bignami disease: a review of CT/MRI confirmed cases. J Neurol Neurosurg Psychiatry 2013; (in press)
    PubMedGoogle Scholar
  • 108 Gáti I, Merkli H, Pál E et al. External ophthalmoplegia associated with Hashimoto's thyroiditis and recovered on corticosteroid treatment. Am J Med Sci 2012; 344: 151-152
    CrossrefPubMedGoogle Scholar
  • 109 Walcott BP, Edlow BL, Xia Z et al. Steroid responsive A3243G mutation MELAS: clinical and radiographic evidence for regional hyperperfusion leading to neuronal loss. Neurologist 2012; 18: 159-170
    CrossrefPubMedGoogle Scholar
  • 110 Schneider-Gold C, Gajdos P, Toyka KV et al. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev 2005; (02) CD002828
    PubMedGoogle Scholar
  • 111 Salinas RA, Alvarez G, Daly F et al. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2010; (03) CD001942 DOI: 10.1002/14651858.CD001942.pub4.
    PubMedGoogle Scholar
  • 112 Escolar DM, Hache LP, Clemens PR et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology 2011; 77: 444-452
    CrossrefPubMedGoogle Scholar
  • 113 Hughes RA, Mehndiratta MM. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2012; 8 CD002062. DOI: 10.1002/14651858.CD002062.pub2.
    PubMedGoogle Scholar
  • 114 Iijima M. Topics of chronic inflammatory demyelinating polyradiculoneuropathy -diagnosis and treatment situation in Japan. Rinsho Byori 2013; 61: 407-413
    PubMedGoogle Scholar
  • 115 Lazarou IN, Guerne PA. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 2013; 40: 550-564
    CrossrefPubMedGoogle Scholar
  • 116 Collins MP, Periquet MI. Non-systemic vasculitic neuropathy. Curr Opin Neurol 2004; 17: 587-598
    CrossrefPubMedGoogle Scholar
  • 117 Paudyal BP, Gyawalee M, Sigdel K. Eosinophilic fascitis: a rare fibrosing disorder. Kathmandu Univ Med J (KUMJ) 2012; 10: 73-75
    PubMedGoogle Scholar
  • 118 Donati D, De Santi L, Ginanneschi F et al. Successful response of non-recovering Ramsay Hunt syndrome to intravenous high dose methylprednisolone. J Neurol Sci 2012; 318: 160-162
    CrossrefPubMedGoogle Scholar